Disruptive mood dysregulation disorder (DMDD) was introduced in DSM-5 and retained in DSM-5-TR to capture children with chronic, severe, non-episodic irritability who were previously — and, the evidence suggested, inappropriately — being diagnosed with pediatric bipolar disorder. The diagnosis sits in the depressive disorders chapter rather than among bipolar and related disorders, a deliberate placement reflecting longitudinal data that these youth more often progress to unipolar depressive and anxiety disorders than to bipolar illness. Clinically, DMDD describes a child aged 6 through 17 with severe recurrent temper outbursts that are out of proportion to provocation, occurring on average three or more times per week, against a persistently irritable or angry mood between outbursts, present across at least two settings for at least twelve months. The diagnosis carries substantial controversy regarding its validity as a distinct entity, its overlap with Oppositional defiant disorder and Attention-deficit/hyperactivity disorder, and the absence of any FDA-approved treatment. The bottom line for the clinician: DMDD is a useful brake on reflexive pediatric bipolar diagnoses, but it is a poorly bounded category whose treatment leans heavily on managing comorbid ADHD, anxiety, and depression while avoiding the harms of antipsychotic polypharmacy.

DMDD is a relatively uncommon but not rare diagnosis in community samples, with prevalence estimates that vary widely depending on whether strict DSM-5 criteria are applied and how impairment is operationalized.

Prevalence

• Three-month point prevalence in community samples of children aged 2-17 ranges from approximately 0.8% to 3.3% depending on age band and ascertainment methods.^1-2
• Six-month to one-year prevalence in school-age children clusters around 1-2% in most studies that apply full DSM-5 criteria.^1-2
• Prevalence is highest in preschool and early school-age samples and declines through adolescence, paralleling the developmental trajectory of severe irritability.²

Demographics

• Boys outnumber girls in clinical samples, though community-based estimates show a narrower sex ratio than is seen in referred cohorts.^1-2
• Onset by definition must be before age 10, and the diagnosis is not made before age 6 or after age 18.³
• Lower socioeconomic status, family adversity, and exposure to harsh or inconsistent parenting are over-represented among affected youth.²

Comorbidity

• Comorbidity is the rule rather than the exception, with most children meeting criteria for at least one other disorder.^1-2
• ODD co-occurs in the majority of cases — by some estimates more than 80% — raising persistent questions about whether DMDD adds incremental information beyond ODD with chronic irritability.^1,4
• ADHD is present in roughly one-quarter to one-half of children with DMDD across samples.^1-2
• Anxiety disorders and major depressive disorder are also common, particularly as affected children approach adolescence.^2,5
• Substance use disorders and suicidal behavior become important comorbidities by mid-adolescence and into early adulthood.⁵

DMDD is best understood as a disorder of severe, chronic irritability whose neurobiology overlaps with — but is not identical to — that of pediatric bipolar disorder, ADHD, and anxiety disorders. The dominant model frames irritability as aberrant responses to frustration and threat, with disrupted top-down regulation by prefrontal circuitry over limbic reactivity.^6-7

Neurobiology

• Functional MRI studies in youth with severe mood dysregulation and DMDD show altered amygdala responses to emotional faces, particularly to ambiguous or negatively valenced stimuli, suggesting heightened threat sensitivity.^6-7
• Frustration paradigms reveal abnormal activation in striatal and prefrontal regions, consistent with impaired processing of reward omission and effortful control.^6-7
• Compared with youth with bipolar disorder, those with chronic irritability show distinct patterns on face-processing and frustration tasks, supporting at least partial neurobiological dissociation between episodic and non-episodic mood pathology.^6-7

Genetics and family history

• Twin studies of irritability as a dimensional trait show moderate heritability, with substantial overlap with the genetic architecture of depression and ADHD.⁸
• Familial risk for DMDD aligns more closely with unipolar depression and anxiety than with bipolar disorder, consistent with the longitudinal phenotypic data.^5,8

Environmental contributors

• Adverse childhood experiences, including maltreatment and exposure to family conflict, are over-represented in clinical samples.²
• Harsh, inconsistent, or coercive parenting interacts with temperamental reactivity to amplify irritability over development.^2,9

Integrative model

• Current frameworks conceptualize DMDD as the severe end of a dimensional irritability phenotype, arising from the interaction of temperamental reactivity, disrupted frustration and threat processing, and family or environmental factors that fail to scaffold emotion regulation.^6-7,9
• This dimensional view underlies the Research Domain Criteria approach, which has largely supplanted categorical research models of pediatric irritability.⁷

DSM-5-TR places DMDD in the depressive disorders chapter and frames it as a diagnosis of chronic, non-episodic irritability with superimposed temper outbursts. The criteria are deliberately restrictive to prevent the diagnosis from sprawling across the irritable-child population.

Core features

• Severe recurrent temper outbursts — verbal rages or physical aggression toward people or property — that are grossly out of proportion in intensity or duration to the situation or provocation.³
• Outbursts are inconsistent with developmental level, meaning they go beyond the typical tantrums of early childhood.³
• Outbursts occur on average three or more times per week.³
• Between outbursts, the child's mood is persistently irritable or angry most of the day, nearly every day, and is observable by others.³

Duration, setting, and age

• Symptoms have been present for at least 12 months, with no symptom-free interval lasting three or more consecutive months.³
• Symptoms are present in at least two of three settings — at home, at school, or with peers — and are severe in at least one.³
• The diagnosis is made between ages 6 and 18, with onset of symptoms before age 10.³

Exclusions

• The diagnosis cannot coexist with bipolar I, bipolar II, oppositional defiant disorder, or intermittent explosive disorder; if criteria for both DMDD and ODD are met, only DMDD is diagnosed.³
• The presence of a single full-duration manic or hypomanic episode (longer than one day) excludes DMDD.³
• DMDD can coexist with major depressive disorder, ADHD, conduct disorder, and substance use disorders.³
• Symptoms must not be better explained by another mental disorder, a substance, or another medical or neurological condition.³

ICD-11 differences

• ICD-11 does not include DMDD as a separate disorder; chronic irritability of the DMDD type is coded under oppositional defiant disorder with chronic irritability-anger, an explicit specifier introduced in ICD-11.¹⁰
• This nomenclature divergence reflects the unresolved debate about whether DMDD adds incremental validity beyond severe ODD.^4,10

The prototypical DMDD presentation is a school-age child whose explosive reactions to minor frustrations have alarmed teachers and exhausted caregivers, set against a background of grumpy, touchy mood that never seems to lift. The clinical picture differs sharply from the discrete manic or hypomanic episodes of bipolar disorder.

Symptom clusters

• Behavioral outbursts include screaming, swearing, throwing objects, hitting, kicking, biting, and property destruction triggered by routine demands or denied requests.^3,11
• Outbursts typically last minutes to under an hour and resolve incompletely, with the child returning to a baseline of irritability rather than calm.¹¹
• Inter-episode mood is described by parents and teachers as cranky, touchy, easily annoyed, and quick to anger, often with an undertone of sadness.^3,11

Functional impact

• School performance suffers from disciplinary actions, peer rejection, and disrupted learning during dysregulated periods.¹¹
• Family functioning is heavily strained, with elevated rates of parental stress, marital conflict, and sibling distress.^2,11
• Peer relationships are typically impoverished, with social rejection compounding depressive symptoms over time.¹¹

Course

• Onset is typically in early to middle childhood, frequently with a prodrome of difficult temperament and ADHD-like symptoms in preschool years.^2,11
• Symptoms tend to attenuate through adolescence in some youth but persist or evolve into depressive and anxiety disorders in others.⁵
• Full bipolar disorder is an uncommon outcome, distinguishing DMDD's longitudinal course from clinician concerns that drove early pediatric bipolar overdiagnosis.⁵

Atypical presentations and red flags

• Episodic, distinct mood elevation with grandiosity, decreased need for sleep, or pressured speech should redirect the workup toward bipolar disorder rather than DMDD.³
• New-onset severe irritability after age 10, especially with neurologic symptoms or cognitive change, warrants a medical workup before ascribing symptoms to DMDD.¹²
• Perpetrator-directed planned aggression, callous-unemotional traits, or fire-setting and animal cruelty point toward conduct disorder rather than DMDD.³

The differential is the heart of DMDD evaluation, because the diagnosis was created precisely to discipline how clinicians think about chronic pediatric irritability. The clinician's job is to distinguish episodic from non-episodic mood pathology, identify treatable comorbidities, and rule out medical mimics.

Pediatric bipolar disorder

• Bipolar I and II require discrete episodes of mania or hypomania with elevated, expansive, or irritable mood plus the B-criteria symptom cluster lasting at least 4 days (hypomania) or 7 days (mania).³
• DMDD is non-episodic by definition; chronic irritability without clear episodes argues against bipolar disorder.^3,5
• Longitudinal data show that children with chronic irritability rarely convert to classic bipolar disorder, undermining the prior practice of treating these youth as having a bipolar-spectrum illness.⁵

Oppositional defiant disorder

• ODD shares the irritable mood and angry behavior dimensions but does not require severe outbursts of DMDD's frequency or intensity.^3-4
• DSM-5-TR forces a single diagnosis when criteria for both are met, with DMDD taking precedence; in clinical practice this means most children meeting DMDD criteria would also have qualified for ODD.^3-4

Intermittent explosive disorder

• IED requires recurrent aggressive outbursts but does not require the persistently irritable inter-episode mood that defines DMDD.³
• IED is not diagnosed below age 6 and is not given alongside DMDD.³

ADHD:

• ADHD-related emotional impulsivity can produce frequent outbursts but typically lacks the sustained between-episode irritability of DMDD.^11,13
• ADHD and DMDD frequently co-occur and both diagnoses can be made when criteria for each are independently met.^3,13

Major depressive disorder and anxiety disorders

• In children, irritability can substitute for depressed mood as the A-criterion for major depressive disorder; episodic irritability with neurovegetative symptoms suggests MDD rather than DMDD.³
• Generalized anxiety and separation anxiety in children frequently present with irritability, particularly when the child is overwhelmed by anticipated stressors.¹¹

Autism spectrum disorder

• Outbursts in ASD are often triggered by sensory overload, change in routine, or communication breakdown rather than ordinary frustration; the chronic irritability pattern of DMDD may not apply.¹⁴
• DMDD can be diagnosed alongside ASD if criteria are met, but careful functional assessment is needed to avoid double-counting ASD-driven dysregulation.¹⁴

Trauma- and stressor-related disorders

• PTSD in children commonly presents with irritability, angry outbursts, hyperarousal, and emotional reactivity, mimicking DMDD.¹⁵
• A trauma history must be explicitly elicited; misdiagnosing a traumatized child with DMDD risks missing trauma-focused treatment.¹⁵

Medical and neurologic mimics

• Hyperthyroidism, anemia, lead exposure, obstructive sleep apnea, and uncontrolled pain can all produce irritability and outbursts in children.¹²
• Seizure disorders, particularly temporal lobe epilepsy, and post-concussive syndromes can drive episodic irritability or aggression.¹²
• Substance use, including stimulant misuse and cannabis withdrawal in adolescents, must be considered in the older end of the age range.¹²

Evaluation requires multi-informant data, careful longitudinal characterization of mood, and a defensible exclusion of bipolar disorder and medical mimics. There is no biomarker for DMDD; the diagnosis is built from history and observation.³

Interview and history

• Obtain detailed parent and teacher reports about outburst frequency, duration, triggers, and inter-episode mood across at least 12 months and at least two settings.^3,11
• Probe explicitly for discrete periods of elevated, expansive, or grandiose mood, decreased need for sleep, pressured speech, and goal-directed activity to evaluate for bipolar disorder.³
• Screen for trauma exposure, attachment disruption, school bullying, and family violence in every case.¹⁵
• Document developmental history, language, sensory issues, and social reciprocity to evaluate for ASD and intellectual disability.¹⁴
• Assess substance use and sleep in older children and adolescents.¹²

Mandatory clinical content

• Functional impairment in academic, family, and peer domains, with examples.^3,11
• Suicidal and aggressive ideation, including planning and access to means.^5,16
• Comorbid ADHD, anxiety, depressive, and disruptive behavior disorders.^1-2
• Prior medication trials, response, and adverse effects, particularly antipsychotic exposure given off-label prescribing patterns in this population.^16-17

Rating scales

• The Affective Reactivity Index (ARI) is a brief parent- and self-report measure of irritability validated for DMDD-relevant phenotypes.¹⁸
• The Child Behavior Checklist (CBCL) and Teacher Report Form quantify externalizing and internalizing symptoms across settings.¹⁹
• The Young Mania Rating Scale (YMRS) and the K-SADS mania module help differentiate non-episodic irritability from manic episodes.²⁰
• Standardized diagnostic interviews such as the K-SADS-PL include DMDD modules and remain the research-standard assessment.²⁰

Physical exam and workup

• Vital signs, growth parameters, and a focused neurologic exam in every case.¹²
• Targeted laboratory testing — TSH, CBC, basic metabolic panel — when history or exam suggests medical contributors; routine extensive labs are not indicated for typical presentations.¹²
• Sleep evaluation, including screening for obstructive sleep apnea, when daytime irritability is prominent.¹²
• Toxicology in adolescents when substance use is suspected.¹²
• EEG and neuroimaging are not part of routine DMDD workup and should be reserved for cases with focal neurologic findings, paroxysmal episodes, or other red flags.¹²

What not to do:

• Do not order routine genetic testing, structural neuroimaging, or extensive autoimmune panels in the absence of specific clinical indicators.¹²
• Do not diagnose DMDD on a single clinical encounter without longitudinal data from at least one non-parent informant.^3,11

No medication is FDA-approved for DMDD, and no psychotherapy has been validated specifically for the diagnosis as defined in DSM-5-TR. Practical management borrows from the evidence bases for ADHD, ODD, anxiety, and depression — the conditions that account for most of DMDD's comorbidity — while explicitly avoiding the antipsychotic-heavy patterns that drove the diagnostic reform in the first place.^16-17

Pharmacotherapy

• Limited evidence supports stimulant treatment of comorbid ADHD as a first pharmacologic step, with reductions in irritability often paralleling ADHD response.^13,17
• Limited evidence suggests SSRIs may help when comorbid anxiety or depressive symptoms are prominent; citalopram with adjunctive stimulant treatment showed benefit on irritability in a randomized trial of severe mood dysregulation, the research phenotype that preceded DMDD.^17,21
• Atypical antipsychotics — risperidone and aripiprazole — have the strongest evidence for reducing severe aggression in disruptive behavior disorders and are sometimes used in DMDD, but their metabolic and neurological harms argue strongly against routine first-line use.^16-17
• Mood stabilizers, including lithium and valproate, lack adequate evidence in DMDD and should not be used to treat the chronic irritability phenotype as if it were a bipolar variant.^16-17
• It is uncertain whether any pharmacologic strategy improves long-term functional outcomes in DMDD; published trials are short and use heterogeneous outcome measures.¹⁷

Psychotherapy

• Some experts recommend parent management training as a first-line intervention, building on its strong evidence base in ODD and disruptive behavior disorders, though high-quality evidence specific to DMDD is lacking.^9,17
• Limited evidence suggests cognitive-behavioral therapy adapted for irritability — including interpretation-bias training and exposure to frustrative non-reward — may reduce irritability in youth with DMDD or severe mood dysregulation.²³
• Dialectical behavior therapy adapted for children (DBT-C) has emerging evidence in pilot trials of severe emotional dysregulation, including in DMDD samples.²⁴
• Family-based interventions addressing parental scaffolding of emotion regulation are commonly recommended given the role of parenting in modulating temperamental reactivity.^9,17

Neuromodulation

• It is uncertain whether neuromodulation strategies have a role in DMDD; the evidence base is essentially absent and these approaches should not be offered outside of research protocols.¹⁷

Adjunctive

• School-based accommodations under an Individualized Education Program or 504 Plan reduce situational triggers and document functional impairment.¹¹
• Sleep, physical activity, and structured routines are reasonable supportive measures, though direct DMDD evidence is limited.^11,17
• Treatment of comorbid sleep-disordered breathing, iron deficiency, or other identified medical contributors can produce meaningful improvement in irritability.¹²

DMDD is a young diagnosis with a thin treatment evidence base, so harms come from two directions: side effects of the medications most often used off-label, and risks of misdiagnosis that misroute care. Both deserve explicit acknowledgment with families.^16-17

Common adverse effects

• Stimulants: appetite suppression, weight loss, insomnia, headache, and increased heart rate and blood pressure.¹³
• SSRIs: gastrointestinal upset, activation, sexual dysfunction in adolescents, and the FDA boxed warning regarding suicidal ideation in youth.²⁵
• Atypical antipsychotics: sedation, weight gain, dyslipidemia, hyperglycemia, hyperprolactinemia, and extrapyramidal symptoms.²²

Serious or rare adverse effects

• Stimulant misuse and diversion in adolescents and household contacts.¹³
• Serotonin syndrome with SSRI combinations or overdose.²⁵
• Tardive dyskinesia, neuroleptic malignant syndrome, and metabolic syndrome with prolonged antipsychotic exposure.²²
• Lithium toxicity, nephrogenic diabetes insipidus, and thyroid dysfunction if mood stabilizers are used inappropriately.²²

Monitoring and discontinuation

• Antipsychotic monitoring requires baseline and scheduled weight, height, BP, fasting glucose, lipids, prolactin when symptomatic, and Abnormal Involuntary Movement Scale assessment.²²
• SSRI discontinuation in youth should be tapered and accompanied by close monitoring for re-emergent depression or suicidality.²⁵
• Stimulant breaks during weekends or summers are sometimes used to mitigate growth effects, though evidence on the necessity of drug holidays is mixed.¹³

Limitations of the evidence base

• Most pharmacologic trials in DMDD are small, short, industry-influenced, or were conducted in the predecessor severe mood dysregulation phenotype rather than in formally diagnosed DMDD.¹⁷
• Long-term outcome data on functional trajectories are limited, particularly into adulthood.^5,17
• Psychotherapy trials suffer from heterogeneous comparators, small samples, and limited replication.^17,23-24
• Diagnostic instability over time complicates trial interpretation, with many participants no longer meeting criteria at follow-up.⁵

DMDD is by definition a childhood and adolescent diagnosis, but several subgroups deserve explicit attention because they shift either the differential or the treatment plan.

Preschool and early school-age children

• The diagnosis cannot be made before age 6, but symptoms must have begun before age 10; preschool clinicians often see prodromal patterns of severe temper outbursts that warrant close follow-up rather than premature diagnosis.^3,11
• Behavioral parent training has the strongest evidence base in this age group and should anchor management.⁹

Adolescents

• The DMDD phenotype evolves through adolescence, with many youth transitioning to depressive and anxiety disorders rather than continuing to meet DMDD criteria.⁵
• Suicidality, self-harm, and substance use become increasingly important to assess.^5,16
• New presentations after age 18 cannot be diagnosed as DMDD; consider depressive, anxiety, personality, and substance use disorders.³

Comorbid neurodevelopmental disorders

• Children with ASD or intellectual disability may have outbursts driven by communication frustration, sensory issues, or routine disruption rather than DMDD-type irritability; the diagnosis can be made if criteria are independently met but requires careful functional assessment.¹⁴
• Stimulant treatment of comorbid ADHD remains relevant but may produce more variable responses in ASD.^13-14

Trauma-exposed youth

• Children with histories of maltreatment, family violence, or chronic adversity may meet DMDD criteria but benefit primarily from trauma-focused interventions.¹⁵
• Trauma-focused CBT and similar evidence-based trauma treatments should be prioritized when a trauma history is identified.¹⁵

Cultural and contextual considerations

• Norms for emotional expression vary substantially across cultures, and clinicians must calibrate severity judgments against the child's family and community context.^2,11
• Disparities in access to behavioral health services and over-prescription of antipsychotics in under-resourced communities are documented and warrant explicit attention.¹⁶

DMDD's longitudinal course was the empirical question that motivated its creation, and the answer has been clarifying: chronic severe irritability is a real, impairing phenotype that does not, for the most part, become bipolar disorder.

Natural history

• Most children diagnosed with DMDD do not meet criteria for the same diagnosis several years later, reflecting both genuine improvement and diagnostic instability.⁵
• Persistent irritability in childhood predicts increased rates of major depressive disorder, generalized anxiety disorder, and disruptive behavior disorders in young adulthood.^5,8
• Conversion to bipolar I or II disorder is uncommon in longitudinal follow-up, contrasting with prior assumptions about pediatric bipolar spectrum.⁵

Functional outcomes

• Educational underachievement, peer rejection, and family conflict are common during the symptomatic period.¹¹
• By young adulthood, affected individuals show elevated rates of unemployment, financial stress, and relationship difficulties relative to peers without childhood irritability.⁵
• Suicide attempts and self-harm are over-represented compared with the general adolescent population.^5,16

Mortality and suicide

• Suicide risk in adolescents with chronic severe irritability is elevated, paralleling the elevated risk in unipolar depression and anxiety disorders that the phenotype predicts.^5,16
• Aggressive behavior and impulsivity contribute to injury risk and unintentional mortality, particularly in adolescence.⁵

Children with DMDD often present to emergency departments during severe outbursts, and the management priorities are different from those for episodic mania or psychosis.

Hospitalization criteria

• Imminent suicide risk with plan or means, severe self-harm, or aggression posing imminent danger to others justify inpatient admission.¹⁶
• Caregiver inability to maintain safety despite outpatient supports is an additional admission criterion in many systems.¹⁶

Suicide risk markers

• Direct verbalization of suicidal intent, specific plan, access to lethal means, prior attempts, and acute psychosocial losses are core risk factors.¹⁶
• Comorbid major depressive disorder, substance use, and recent self-harm significantly elevate near-term risk.^5,16

Agitation management

• Verbal de-escalation, environmental modification, and engagement of caregivers should be the first-line approach for an outburst in an emergency setting.²⁶
• Pharmacologic management of acute agitation in pediatric patients typically uses an oral antihistamine such as diphenhydramine, an oral benzodiazepine such as lorazepam, or an oral atypical antipsychotic depending on age and severity, with intramuscular routes reserved for severe or refractory agitation.²⁶
• Restraint and seclusion should be used only when less restrictive measures have failed, and require institutional protocols and debriefing.²⁶

DMDD remains one of the most debated additions to DSM-5, and clinicians should be familiar with the major controversies because they shape both diagnostic practice and the framing of treatment goals with families.

Diagnostic validity

• Critics argue that DMDD does not meet standard criteria for diagnostic validity — it lacks distinct biology, clear treatment specificity, or unique longitudinal course separable from comorbid ODD, ADHD, anxiety, and depression.^4,27
• Supporters counter that it serves a useful clinical purpose by providing a non-bipolar home for chronically irritable youth and curtailing inappropriate bipolar diagnoses and antipsychotic prescribing.²⁷

Overlap with ODD

• Most children meeting DMDD criteria also meet ODD criteria, raising the question of whether DMDD is best understood as severe ODD with chronic irritability.^1,4
• ICD-11 took precisely this approach, codifying chronic irritability as an ODD specifier rather than a separate disorder.¹⁰

Treatment evidence base

• No medication is FDA-approved for DMDD, and trials specifically in DMDD-defined samples remain few and small.¹⁷
• Most pharmacologic recommendations are extrapolated from related conditions, raising questions about generalizability.¹⁷

Pediatric bipolar disorder backdrop

• DMDD was created in part to address a marked rise in pediatric bipolar diagnoses and antipsychotic prescribing during the 1990s and 2000s; whether the diagnosis has succeeded in shifting practice is debated.^16,27

Stigma and labeling

• Some clinicians worry that DMDD pathologizes severe but developmentally bound irritability, while others argue that a formal diagnosis legitimizes care and supports access to services.²⁷

• DMDD was added in DSM-5 and retained in DSM-5-TR specifically to reduce overdiagnosis of pediatric bipolar disorder in chronically irritable children.^3,27
• DMDD is classified within the depressive disorders chapter, not the bipolar disorders chapter, reflecting longitudinal data on outcomes.^3,5
• DMDD requires severe temper outbursts averaging three or more times per week, plus a persistently irritable or angry mood between outbursts, for at least 12 months in two or more settings.³
• DMDD is diagnosed only between ages 6 and 18, with onset before age 10.³
• A single full-duration manic or hypomanic episode excludes DMDD.³
• DMDD and ODD cannot be diagnosed together; if both criteria sets are met, only DMDD is diagnosed.³
• DMDD can be diagnosed alongside ADHD, MDD, conduct disorder, and substance use disorders.³
• ICD-11 does not include DMDD; it codes chronic irritability under an ODD specifier instead.¹⁰
• Children with DMDD more often progress to unipolar depression and anxiety disorders than to bipolar disorder.⁵
• No medication is FDA-approved for DMDD; treatment focuses on optimizing comorbid ADHD, anxiety, and depressive disorder management.¹⁷
• Atypical antipsychotics carry significant metabolic, neurological, and prolactin-related risks in youth and should not be first-line for DMDD.^16-17,22
• Parent management training is widely recommended as a first-line non-pharmacologic intervention based on the broader disruptive behavior literature.^9,17
• Trauma history must be elicited in every chronic-irritability evaluation; PTSD frequently mimics DMDD in children.¹⁵
• The Affective Reactivity Index is a validated brief measure for irritability relevant to DMDD assessment.¹⁸

No external funding. No conflicts of interest declared. Peer-review status: pending.